Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson to Invest $1 Billion in COVID-19 Vaccine Development

By Cory Renauer - Mar 30, 2020 at 3:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical giant is building capacity to produce 1 billion doses of an experimental vaccine before it even knows if the vaccine works.

The world's largest healthcare company didn't get this big by gambling, but it just made a huge bet on an experimental coronavirus vaccine. 

On Monday, Johnson & Johnson (JNJ 0.89%) selected a lead vaccine candidate for SARS-CoV-2, the novel coronavirus responsible for COVID-19, and announced it will rapidly create enough manufacturing capacity to deliver over 1 billion doses of it -- even though the vaccine won't be ready for human trials until September. 

In other words, the company's going to mass-produce the vaccine before it has evidence it works.

A COVID-19 sample

Image source: Getty Images.

A big deal

Normally, drugmakers wait for positive results from controlled clinical trials before they even think about breaking ground on facilities meant to mass-produce a potential new drug. Nonetheless, Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA) have committed more than $1 billion to co-fund development of this coronavirus vaccine candidate, and are scaling up facilities to produce it in quantity immediately. So there will be warehouses full of the vaccine candidate by the time the data reveals whether or not it successfully prevents COVID-19. 

If clinical trials succeed, Johnson & Johnson thinks the vaccine could be ready for emergency use in early 2021. Setting such a short timeline for a treatment any other indication would make analysts laugh, but the FDA has been willing to be flexible in regards to attempts to combat the COVID-19 pandemic.

The FDA recently granted its first emergency use authorizations for therapeutic products to treat hospitalized COVID-19 patients. The agency granted the authorization to two decades-old malaria drugs, despite sufficient data from studies with randomized control groups to show that the treatments are effective. 

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$167.57 (0.89%) $1.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.